Journal Logo

THE SIGNIFICANCE OF CD43, CD81, CD200, AND ROR1 FOR DIFFERENTIAL DIAGNOSIS OF CLL AS MULTICOLOR FLOW CYTOMETRY

PB1887

Falay, M.1; Serdar, M.2; Dagdas, S.1; Pepeler, S.1; Ucar, M. A.1; Ozet, G.1

doi: 10.1097/01.HS9.0000566052.22020.95
Publication Only: Chronic lymphocytic leukemia and related disorders - Biology & translational research
Free

1hematology, ankara numune education and resarch hospital, Ankara

2Biochemistry, Acıbadem University Med. Faculty, Istanbul, Turkey

Back to Top | Article Outline

Background:

The scoring system used for CLL cannot make an accurate diagnosis in some cases. Novel markers are available for the differential diagnosis of CLL, especially from MCL. However, these markers are still not incorporated into diagnostic algorithms.

Back to Top | Article Outline

Aims:

We investigated the role of CD43, CD81, CD200, and ROR1 for the differential diagnosis of CLL and their expression in non-CLL cases.

Back to Top | Article Outline

Methods:

: We investigated the role of CD43, CD81, CD20, and ROR1 in the differential diagnosis of CLL by incorporating them into the diagnostic panel after studying peripheral blood or bone marrow samples of 165 patients with 8 color flow cytometry.

Back to Top | Article Outline

Results:

CD43 positivity was sensitive but had a lower specificity for CLL. It had a high diagnostic value for CLL (sensitivity 100%, specificity 88.5%, AUC 98.0%). CD200 was a specific marker for CLL (sensitivity 98%, specificity 90%, AUC: 96%). CD81 expression was highest in the MCL cases, with a median expression rate of 68.5% (range: 54-82.5%). It was negative in all CLL cases. For CLL, CD81 negativity had a sensitivitity of 95%, a specificity of 82%, and an AUC of 92%. ROR1 was positive in all CLL and MCL cases. CD79b, on the other hand, was a fairly sensitive and specific marker for MCL.

Back to Top | Article Outline

Summary/Conclusion:

CD43, CD81, CD200, and ROR1 should be incorporated into diagnostic algorithms for the differential diagnosis of CLL, especially from MCL.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.